semaglutide globus sensation is a GLP-1 Receptor Agonist for T2DM and Obesity Research Semaglutide Tablets

10.1007/s00213-020-05610-z 202 YaoL.RuifangS.XiaopingL.LeiW.HengyingC.SiwenS.et al (2022)

Demand for these three GLP-1 brands, across their various brands and formulations, has led to unprecedented levels of media attention and unsolicited celebrity endorsements that has resulted in unexpected and intermittent supply shortages

The FDA has given compounders time to wind down semaglutide copies, saying it wont take enforcement actions against a category of state-licensed compounders until April 22 and wont take actions against another category known as outsourcing facilities until May 22

2025 15 April

Table 2 Preclinical sulforaphane studies

Not for injection into humans or animals